Literature DB >> 28887808

Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Xuying Pei1, Xiangyu Zhao1, Yu Wang1, Lanping Xu1, Xiaohui Zhang1, Kaiyan Liu1, Yingjun Chang2, Xiaojun Huang3,4.   

Abstract

To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution (IR) in 144 patients who received allogeneic stem cell transplantation (allo- SCT) and without showing any of the following events: poor graft function, grades II‒IV acute graft-versus-host disease (GVHD), serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3+ Tcells, CD8+ T cells, and CD19+ B cells, and very slow in CD4+ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune cells need not reach those in healthy donor in the first year after transplantation.We suggest that data from this recipient cohort should be used as reference values for post-transplant immune cell counts in patients receiving HSCT.

Entities:  

Keywords:  event-free patients; hematopoietic stem cell transplantation; immune reconstitution; reference range

Mesh:

Substances:

Year:  2017        PMID: 28887808     DOI: 10.1007/s11684-017-0548-1

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  32 in total

1.  Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.

Authors:  L Bühlmann; A S Buser; N Cantoni; S Gerull; A Tichelli; A Gratwohl; M Stern
Journal:  Bone Marrow Transplant       Date:  2010-11-29       Impact factor: 5.483

2.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

3.  Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.

Authors:  Sophie Servais; Etienne Lengline; Raphaël Porcher; Maryvonnick Carmagnat; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontebrune; Emmanuel Clave; Guitta Maki; Clémence Granier; Alienor Xhaard; Nathalie Dhedin; Jean-Michel Molina; Antoine Toubert; Hélène Moins-Teisserenc; Gérard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-07       Impact factor: 5.742

4.  Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts.

Authors:  J Storek; T Gooley; R P Witherspoon; K M Sullivan; R Storb
Journal:  Am J Hematol       Date:  1997-02       Impact factor: 10.047

Review 5.  Immune reconstitution after hematopoietic cell transplantation.

Authors:  Mark Bosch; Faisal M Khan; Jan Storek
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

6.  Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.

Authors:  Marie Robin; Raphaël Porcher; Renato De Castro Araujo; Régis Peffault de Latour; Agnès Devergie; Vanderson Rocha; Jérome Larghero; Lionel Adès; Patricia Ribaud; Jean-Yves Mary; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-07       Impact factor: 5.742

7.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

Authors:  Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek
Journal:  Cytotherapy       Date:  2012-09-18       Impact factor: 5.414

Review 8.  Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.

Authors:  Jan Storek; Michelle Geddes; Faisal Khan; Bertrand Huard; Claudine Helg; Yves Chalandon; Jakob Passweg; Eddy Roosnek
Journal:  Semin Immunopathol       Date:  2008-10-24       Impact factor: 9.623

9.  European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.

Authors:  Martin Hoenigl; Volker Strenger; Walter Buzina; Thomas Valentin; Christoph Koidl; Albert Wölfler; Katharina Seeber; Angelika Valentin; Anna T Strohmeier; Ines Zollner-Schwetz; Reinhard B Raggam; Christian Urban; Cornelia Lass-Flörl; Werner Linkesch; Robert Krause
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

10.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han; Yu-Hong Chen; Xiao-Hui Zhang; Dao-Pei Lu
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

View more
  5 in total

1.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

2.  How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard E Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

3.  Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.

Authors:  Yoshinobu Maeda
Journal:  J Clin Exp Hematop       Date:  2021-02-06

4.  Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment.

Authors:  Dao-Xing Deng; Shuang Fan; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xu-Ying Pei; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

Review 5.  Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.

Authors:  Susanne H C Baumeister; Benedetta Rambaldi; Roman M Shapiro; Rizwan Romee
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.